JAMA Network
About The Study: This study found a profound decrease in the utilization of metabolic bariatric surgery, with a 34.1% decrease from 2022 to 2024, while glucagon-like peptide-1 receptor agonist (GLP-1) use increased by 140.4% over the same period. Given the year-on year declines in metabolic bariatric surgery utilization, these trends may continue given the persistent and growing prescribing of GLP-1s.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
